guest lecture Flashcards

(31 cards)

1
Q

Multiple sclerosis

A

Chronic autoimmune disease of the** central nervous system**

Destruction of myelin sheath around neurons
→ lesions can be seen by MRI

Nerves cannot properly pass along their
signals (sclerosis = scar tissue)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

MS

range of symptoms

A
  • pain
  • fatigue
  • tingling麻刺感
  • impaired gait (pattern of walking)
  • vision problems
  • bladder problems
  • dizziness
  • cognitive and mood problems
  • paralysis瘫痪
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

MS and immune system

A

Inflammation causes increased recruitment of other immune cells

Lymphocytes cross the blood-brain barrier and autoreactive CD4+ T cells reencounter their specific autoantigen presented by MHC II on macrophages

Autoreactive T cells, B cells and innate cells lead to demyelination
Treg can regulate the inflammation for a bit

unknown trigger, microglial express the self-peptide recognize by the autoimmune T cells

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

MS

() express the self peptide

A

microglial

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

MS

() produce myelin and support neurons

A

oligodendrocyte

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

type of MS

A

~ 85% of patients suffer from relapsing-remitting MS: experience periods when symptoms get better (remission) followed by attacks (relapse)

relapsing-remitting MS
primary progressive MS
progressive-relapsing MS
secondary progressive Ms

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

MS

Episodes of relapses (attacks) which may or may not leave permanent disability followed by periods of remission

A

Relapsing-remitting MS

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

MS

Steady increase in disability with no relapse or remissions

A

Primary progressive MS

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

MS

steady increase in disability with
subsequent relapses and no remissions

A

Progressive-relapsing MS

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

MS

Initial relapsing-remitting MS that begins to
steadily increase in disability without periods of remission

A

Secondary progressive MS

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Diagonosing MS

A
  • MRI
  • Vision, coordination, sense of balance
  • Spinal Tap or Lumbar puncturecollecting cerebral fluid to determine how much inflammation is in your CNS
  • Blood test – to rule out other diseases that might have similar symptoms
  • Evoked potential tests – electric signals used to measure how quickly and accurately the nervous system responds
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

MS

treatment

A

reduces relapses by ~30%
weekly injection
* IFN beta therapy
* corticosteroids therapy

reduces relaspses by 50%
oral pills
more recent therapy
fewer side effects
* dimethyl fumarate therapy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

MS

IFN beta therapy potential mechanism

A
  • Control the secretion of pro and anti inflammatory cytokines
  • Reducing the ability of lymphocytes to cross blood-brain barrier
  • Affecting APC function
  • May inhibit some T cell differentiation & increase T cell apoptosis
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

MS

corticosteriod therapy

A

immunosuppressantreduces inflammation

caused by pro-inflammatory cytokines, increases induction of apoptosis in
lymphocytes
, reduces migration of leukocytes to the brain

have risk to the patient because caused immunocompromised

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

MS

dimethyl fumarate therapy

A
  • Anti-inflammatory effects: can suppress the production of pro-inflammatory cytokines
  • Stimulate Tregs
  • Induce changes in maturation, availability and antigen-presenting capacity of APCs
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

other therapy of MS

A

Various components of the immune system are targeted by these MS therapies, which can lead to immunosuppression

17
Q

many factors can contribute to MS progression

A

smoking
pathogens
gut microbiome
lipids and lipoproteins
hypertension
genetics
diabetes
diet
physical inactivity
body mass index

18
Q

ITP

A

immune thrombocytopenia

an acquired autoimmune disorder in which the body’s immune system destroys healthy platelets, leaving the patient at risk for spontaneous bleeding and bruising (挫伤)

19
Q

Cause of ITP

A

evironmental exposures (viral infection, vaccine, toxins, stress)

genetic predisposition (mutation family)

loss of immune self-tolerance (antigen mimicry, dysfunction of Tregs, anti-platet IgG antibody)

20
Q

pathophysiology病理生理学 of ITP

A

increased platelet destruction: B cell make antiplatelet antibodies, platelet moved
decreased platelet production: CTL destroy the megakaryocytes in the bone marrow, magakaryocytes produce platelet

=low platelet

21
Q

epidemiology 流行病学 of ITP

A
  • ITP affects ~5 in 100,000 children per year
  • Most commonly between age 2-5 years
  • Will often self-resolve within 3-12 months
  • No way to predict who will be acute vs chronic

prevalence of adult with ITP at any time: 9.5 cases per 100,000

22
Q

signs and symptoms of ITP

A

Purpura (bruising)
Petechiae
Nosebleeds
Heavy menstrual bleeding
Bleeding in the mouth or gums
Blood in emesis, urine or stool
Fatigue
Rarely, intracranial bleeding

The patient could also be asymptomatic!

23
Q

lab finding of diagnosis of ITP

A

CBC and smear:
➢ Platelet count < 100 x 109/L
➢ Normal WBC, normal Hb, normal cell morphology
➢ Anemia only present if severe bleeding

24
Q

major causes of ITP in children

A

Primary ITP

Primary immune deficiency or immune dysregulation disorder (PID)

Inherited Platelet Disorders (IPD)

25
# ITP inborn errors of immunity
infections, allergy, autoimmunity, autoinflammation, malignancy (cancer)
26
# Fact ITP can sometimes be the first presentation of an inborn error of immunity (IEI)
27
# ITP IEI consequence
immunodeficiency disorder or immune dysregulation disorder
28
general treatment goal of ITP
Treat bleeding symptoms, NOT platelet count Improve quality of life Shared decision-making should incorporate each patient/family’s values and preferences
29
treatment options
first line: **observation** **IVIG** **Corticosteroids** Second line: **TPO-agents** (thrombopoietin): TPO is a hormone tell bone marrow to produce platelet **Rituximab**: specific mediaction or monoclonal antibody, target CD20 (B cell marker) **splenectomy**
30
immunology importance
1.better understand human disease 2.predic symptom 3.treatment
31